The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Open accessAbstract
Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors examined to date are related to early recurrence while those related to late recurrence and their countermeasures remain unclear. Therefore, we examined the factors related to late recurrence. Patients and Methods: From January 1980 to August 2012, 4,774 patients who underwent primary treatment and estrogen (ER) and progesterone receptor (PgR) assessment were enrolled in this study. The patients were divided into two groups, those with a follow-up period <10 years and those without any recurrence at 10 years but who continued follow-up examinations. Recurrence occurred in 711 patients followed up for <10 years and in 51 patients for ≥10 years. Results: The overall 10-year cumulative disease-free survival rate was 79.5%, and the recurrence rate at ≥10 years was 5.8%. A multivariate analysis revealed that the factors related to late recurrence were PgR positivity and positive nodes. This result differed from that for early recurrence in terms of ER/PgR, Ki-67 index and p53 overexpression. Conclusion: PgR positivity and lymph node metastases significantly correlated with late recurrence. Therefore, it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Research works printed but not linked: 3
- 10.1007/s10147-006-0601-6 · doi:10.1007/s10147-006-0601-6
- 10.1186/1477-7819-9-131 · doi:10.1186/1477-7819-9-131
- 10.1186/bcr2143 · doi:10.1186/bcr2143
Cited by
Items 601–700 of 787
The Genetic Epidemiology of Breast Cancer Genes
Thompson, D., & Easton, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048770.90334.3b · Cited by 257
Modeling tumor phenotypes in vitro with three-dimensional bioprinting
Langer, E. M., Allen-Petersen, B. L., King, S. M., Kendsersky, N. D., Turnidge, M. A., Kuziel, G. M., Riggers, R., Samatham, R., Amery, T. S., Jacques, S. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.090 · Cited by 256
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis
Welcsh, P. L., Lee, M. K., Gonzalez-Hernandez, R. M., Black, D. J., Mahadevappa, M., Swisher, E. M., Warrington, J. A., & King, M.-C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062181799 · Cited by 256
Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0131-9 · Cited by 255
Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8619 · Cited by 244
Luminal A Breast Cancer and Molecular Assays: A Review
Gao, J. J., & Swain, S. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0535 · Cited by 254
Pitroda, S. P., Khodarev, N. N., Huang, L., Uppal, A., Wightman, S. C., Ganai, S., Joseph, N., Pitt, J., Brown, M., Forde, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04278-6 · Cited by 254
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
RetractedHypoxia-inducible factor 1 and breast cancer metastasis
Liu, Z.-J., Semenza, G. L., & Zhang, H.-F. (2015) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b1400221 · Cited by 252
Targeting TACE-dependent EGFR ligand shedding in breast cancer
Kenny, P. A., & Bissell, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29518 · Cited by 252
Barutcu, A. R., Lajoie, B. R., McCord, R. P., Tye, C. E., Hong, D., Messier, T. L., Browne, G., van Wijnen, A. J., Lian, J. B., Stein, J. L., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0768-0 · Cited by 250
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes
Long, S. A., Thorpe, J., DeBerg, H. A., Gersuk, V., Eddy, J. A., Harris, K. M., Ehlers, M., Herold, K. C., Nepom, G. T., & Linsley, P. S. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai7793 · Cited by 250
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249
Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing
Helman, E., Lawrence, M. S., Stewart, C., Sougnez, C., Getz, G., & Meyerson, M. (2014) · Genome Research · doi:10.1101/gr.163659.113 · Cited by 240
Metabolic reprogramming in triple-negative breast cancer
Wang, Z., Jiang, Q., & Dong, C. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0210 · Cited by 248
Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J. H., Lee, S.-H., Han, W., Kim, D.-W., Kim, T.-Y., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2834 · Cited by 235
Bhardwaj, P., Au, C. C., Benito-Martin, A., Ladumor, H., Oshchepkova, S., Moges, R., & Brown, K. A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.002 · Cited by 233
Metabolic reprogramming in triple-negative breast cancer
Sun, X., Wang, M., Wang, M., Yu, X., Guo, J., Sun, T., Li, X., Yao, L., Dong, H., & Xu, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00428 · Cited by 243
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Rahmioglu, N., Fassbender, A., Vitonis, A. F., Tworoger, S. S., Hummelshoj, L., D'Hooghe, T. M., Adamson, G. D., Giudice, L. C., Becker, C. M., Zondervan, K. T., et al. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1208 · Cited by 227
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Gardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
Noorbakhsh, J., Farahmand, S., Foroughi pour, A., Namburi, S., Caruana, D., Rimm, D., Soltanieh-ha, M., Zarringhalam, K., & Chuang, J. H. (2020) · Nature Communications · doi:10.1038/s41467-020-20030-5 · Cited by 206
Chen, J. C., Alvarez, M. J., Talos, F., Dhruv, H., Rieckhof, G. E., Iyer, A., Diefes, K. L., Aldape, K., Berens, M., Shen, M. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.021 · Cited by 188
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0900 · Cited by 193
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Telonis, A. G., Loher, P., Honda, S., Jing, Y., Palazzo, J., Kirino, Y., & Rigoutsos, I. (2015) · Oncotarget · doi:10.18632/oncotarget.4695 · Cited by 191
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174
Middlebrooks, C. D., Banday, A. R., Matsuda, K., Udquim, K.-I., Onabajo, O. O., Paquin, A., Figueroa, J. D., Zhu, B., Koutros, S., Kubo, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3670 · Cited by 185
Collins, G. S., Ogundimu, E. O., Cook, J. A., Manach, Y. L., & Altman, D. G. (2016) · Statistics in Medicine · doi:10.1002/sim.6986 · Cited by 185
Gilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184
RetractedMolecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
A comprehensive analysis of breast cancer microbiota and host gene expression
Thompson, K. J., Ingle, J. N., Tang, X., Chia, N., Jeraldo, P. R., Walther-Antonio, M. R., Kandimalla, K. K., Johnson, S., Yao, J. Z., Harrington, S. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188873 · Cited by 183
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
Lanning, N. J., Castle, J. P., Singh, S. J., Leon, A. N., Tovar, E. A., Sanghera, A., MacKeigan, J. P., Filipp, F. V., & Graveel, C. R. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0168-x · Cited by 175
Lightbody, G., Haberland, V., Browne, F., Taggart, L., Zheng, H., Parkes, E., & Blayney, J. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby051 · Cited by 173
An integrative multi-scale analysis of the dynamic DNA methylation landscape in aging
Yuan, T., Jiao, Y., de Jong, S., Ophoff, R. A., Beck, S., & Teschendorff, A. E. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1004996 · Cited by 155
In Vivo Regulation of Human Skeletal Muscle Gene Expression by Thyroid Hormone
Clément, K., Viguerie, N., Diehn, M., Alizadeh, A., Barbe, P., Thalamas, C., Storey, J. D., Brown, P. O., Barsh, G. S., & Langin, D. (2002) · Genome Research · doi:10.1101/gr.207702 · Cited by 169
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
Zhu, Y., Li, H., Guo, W., Drukker, K., Lan, L., Giger, M. L., & Ji, Y. (2015) · Scientific Reports · doi:10.1038/srep17787 · Cited by 165
Tang, W., Zhou, M., Dorsey, T. H., Prieto, D. A., Wang, X. W., Ruppin, E., Veenstra, T. D., & Ambs, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0602-x · Cited by 162
Looking beyond the hype: applied AI and machine learning in translational medicine
Toh, T. S., Dondelinger, F., & Wang, D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.027 · Cited by 159
Determining breast cancer biomarker status and associated morphological features using deep learning
Gamble, P., Jaroensri, R., Wang, H., Tan, F., Moran, M., Brown, T., Flament-Auvigne, I., Rakha, E. A., Toss, M., Dabbs, D. J., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00013-3 · Cited by 154
Zhao, Q., Shi, X., Xie, Y., Huang, J., Shia, B., & Ma, S. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbu003 · Cited by 154
Lipsyc-Sharf, M., de Bruin, E. C., Santos, K., McEwen, R., Stetson, D., Patel, A., Kirkner, G. J., Hughes, M. E., Tolaney, S. M., Partridge, A. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00908 · Cited by 152
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Takaku, M., Grimm, S. A., Shimbo, T., Perera, L., Menafra, R., Stunnenberg, H. G., Archer, T. K., Machida, S., Kurumizaka, H., & Wade, P. A. (2016) · Genome Biology · doi:10.1186/s13059-016-0897-0 · Cited by 151
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Ferrari, A., Vincent-Salomon, A., Pivot, X., Sertier, A.-S., Thomas, E., Tonon, L., Boyault, S., Mulugeta, E., Treilleux, I., MacGrogan, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms12222 · Cited by 150
Truong, D. D., Kratz, A., Park, J. G., Barrientos, E. S., Saini, H., Nguyen, T., Pockaj, B., Mouneimne, G., LaBaer, J., & Nikkhah, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2293 · Cited by 149
The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models
Kattan, M. W., & Gerds, T. A. (2018) · Diagnostic and Prognostic Research · doi:10.1186/s41512-018-0029-2 · Cited by 149
EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis
Verma, A., Singh, A., Singh, M. P., Nengroo, M. A., Saini, K. K., Satrusal, S. R., Khan, M. A., Chaturvedi, P., Sinha, A., Meena, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35059-x · Cited by 148
Guo, W., Li, H., Zhu, Y., Lan, L., Yang, S., Drukker, K., Morris, E. A., Burnside, E. S., Whitman, G. J., Giger, M. L., et al. (2015) · Journal of Medical Imaging · doi:10.1117/1.jmi.2.4.041007 · Cited by 148
Merino, D., Weber, T. S., Serrano, A., Vaillant, F., Liu, K., Pal, B., Di Stefano, L., Schreuder, J., Lin, D., Chen, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08595-2 · Cited by 145
Predictability of human differential gene expression
Crow, M., Lim, N., Ballouz, S., Pavlidis, P., & Gillis, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802973116 · Cited by 117
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131
Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency
Suzuki, M., Mose, E. S., Montel, V., & Tarin, D. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060053 · Cited by 136
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform
Lanz, H. L., Saleh, A., Kramer, B., Cairns, J., Ng, C. P., Yu, J., Trietsch, S. J., Hankemeier, T., Joore, J., Vulto, P., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3709-3 · Cited by 135
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Littlefield, P., Liu, L., Mysore, V., Shan, Y., Shaw, D. E., & Jura, N. (2014) · Science Signaling · doi:10.1126/scisignal.2005786 · Cited by 126
The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
Weigelt, B., Bi, R., Kumar, R., Blecua, P., Mandelker, D. L., Geyer, F. C., Pareja, F., James, P. A., kConFab Investigators, Couch, F. J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy028 · Cited by 128
TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex
Lee, W. H., Choong, L. Y., Mon, N. N., Lu, S., Lin, Q., Pang, B., Yan, B., Krishna, V. S. R., Singh, H., Tan, T. Z., et al. (2016) · Scientific Reports · doi:10.1038/srep27903 · Cited by 125
Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00728-9 · Cited by 124
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
An approach for normalization and quality control for NanoString RNA expression data
Bhattacharya, A., Hamilton, A. M., Furberg, H., Pietzak, E., Purdue, M. P., Troester, M. A., Hoadley, K. A., & Love, M. I. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa163 · Cited by 122
Transforming Epidemiology for 21st Century Medicine and Public Health
Khoury, M. J., Lam, T. K., Ioannidis, J. P. A., Hartge, P., Spitz, M. R., Buring, J. E., Chanock, S. J., Croyle, R. T., Goddard, K. A., Ginsburg, G. S., et al. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0146 · Cited by 119
The Roles of MicroRNAs in Breast Cancer
Takahashi, R.-U., Miyazaki, H., & Ochiya, T. (2015) · Cancers · doi:10.3390/cancers7020598 · Cited by 116
Kim, J.-Y., Jeong, H. S., Chung, T., Kim, M., Lee, J. H., Jung, W. H., & Koo, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.17775 · Cited by 115
Crawford, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00068 · Cited by 108
Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer
Lukey, M. J., Cluntun, A. A., Katt, W. P., Lin, M.-C. J., Druso, J. E., Ramachandran, S., Erickson, J. W., Le, H. H., Wang, Z.-E., Blank, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.076 · Cited by 103
Circulating Tumor Cells: Fluid Surrogates of Solid Tumors
Thiele, J.-A., Bethel, K., Králíčková, M., & Kuhn, P. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100256 · Cited by 107
Group lasso regularized deep learning for cancer prognosis from multi-omics and clinical features
Xie, G., Dong, C., Kong, Y., Zhong, J. F., Li, M., & Wang, K. (2019) · Genes · doi:10.3390/genes10030240 · Cited by 102
Seo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Wen, X., Pu, H., Liu, Q., Guo, Z., & Luo, D. (2022) · Cancers · doi:10.3390/cancers14246025 · Cited by 99
A myriad of roles of miR-25 in health and disease
Sárközy, M., Kahán, Z., & Csont, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24662 · Cited by 99
Clift, A. K., Dodwell, D., Lord, S., Petrou, S., Brady, M., Collins, G. S., & Hippisley-Cox, J. (2023) · BMJ · doi:10.1136/bmj-2022-073800 · Cited by 97
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H.-W. (2018) · Oncogene · doi:10.1038/s41388-018-0132-4 · Cited by 96
A meta-learning approach for genomic survival analysis
Qiu, Y. L., Zheng, H., Devos, A., Selby, H., & Gevaert, O. (2020) · Nature Communications · doi:10.1038/s41467-020-20167-3 · Cited by 96
Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., Maughan, T., McDade, S. S., Johnston, P. G., Longley, D. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15657 · Cited by 94
Ganetespib: research and clinical development
Modi, S., & Jhaveri, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s65804 · Cited by 92
An integrative deep learning framework for classifying molecular subtypes of breast cancer
Mohaiminul Islam, M., Huang, S., Ajwad, R., Chi, C., Wang, Y., & Hu, P. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.005 · Cited by 90
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Hurtado-de-Mendoza, A., Cabling, M. L., Lobo, T., Dash, C., & Sheppard, V. B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.006 · Cited by 79
Zhou, J. X., Taramelli, R., Pedrini, E., Knijnenburg, T., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09307-w · Cited by 85
Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells
Peters, A. A., Jamaludin, S. Y. N., Yapa, K. T. D. S., Chalmers, S., Wiegmans, A. P., Lim, H. F., Milevskiy, M. J. G., Azimi, I., Davis, F. M., Northwood, K. S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.234 · Cited by 85
Beyond Endometriosis Genome-Wide Association Study: From Genomics to Phenomics to the Patient
Rahmioglu, N., Morris, A., Nyholt, D., Montgomery, G., Becker, C., Missmer, S., & Zondervan, K. (2016) · Seminars in Reproductive Medicine · doi:10.1055/s-0036-1585408 · Cited by 84
Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4925-1 · Cited by 83
Huang, Y., Wei, L., Hu, Y., Shao, N., Lin, Y., He, S., Shi, H., Zhang, X., & Lin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706733 · Cited by 82
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer
Bak, M. J., Das Gupta, S., Wahler, J., & Suh, N. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.001 · Cited by 80
Franks, J. M., Martyanov, V., Cai, G., Wang, Y., Li, Z., Wood, T. A., & Whitfield, M. L. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40898 · Cited by 80
Di Meglio, A., Havas, J., Gbenou, A. S., Martin, E., El-Mouhebb, M., Pistilli, B., Menvielle, G., Dumas, A., Everhard, S., Martin, A.-L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00277 · Cited by 76
Bower, J. J., Vance, L. D., Psioda, M., Smith-Roe, S. L., Simpson, D. A., Ibrahim, J. G., Hoadley, K. A., Perou, C. M., & Kaufmann, W. K. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0009-7 · Cited by 76
Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells
Yoh, K. E., Regunath, K., Guzman, A., Lee, S.-M., Pfister, N. T., Akanni, O., Kaufman, L. J., Prives, C., & Prywes, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613417113 · Cited by 75
Beversdorf, D. Q., & MISSOURI AUTISM SUMMIT CONSORTIUM* (2016) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000351 · Cited by 74
Machine learning in prostate MRI for prostate cancer: current status and future opportunities
Li, H., Lee, C. H., Chia, D., Lin, Z., Huang, W., & Tan, C. H. (2022) · Diagnostics · doi:10.3390/diagnostics12020289 · Cited by 74
Bright, E. E., Finkelstein, L. B., Nealis, M. S., Genung, S. R., Wrigley, J., Gu, H. C. J., Schmiege, S. J., & Arch, J. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00697 · Cited by 74
Metadata
- Authors
- Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 85
- Issue
- 2
- Pages
- 100-110
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2044702943
- Cited by
- 13,166
- References
- 236
- FWCI
- 323.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.